Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.85 |
| ▸ | CHRM3 known ✓ | P20309 | 18/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4232767 | 0.96 | CHRM3 (0.79) | CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL13805503 | 0.95 | CHRM2 (0.85) | CHRM2CHRM1CHRM3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4232784 | 0.92 | CHRM2 (1.00) | CHRM2CHRM1CHRM3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4241251 | 0.91 | CHRM2 (0.87) | CHRM2CHRM1CHRM3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4232783 | 0.90 | CHRM2 (0.96) | CHRM2CHRM1CHRM3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4232313 | 0.90 | CHRM2 (0.95) | CHRM2CHRM1CHRM3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4241248 | 0.89 | CHRM2 (0.84) | CHRM2CHRM1CHRM3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4232311 | 0.88 | CHRM2 (0.91) | CHRM2CHRM1CHRM3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4235060 | 0.88 | CHRM2 (0.89) | CHRM2CHRM1CHRM3 | |
| Trifluoroacetic Acid SCHEMBL4240137 | 0.88 | CHRM2 (0.81) | CHRM2CHRM1CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090142279-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | US | claimed |
| EP-1827439-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-09-05 | — | — | EP | claimed |
| WO-2006055503-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-05-26 | — | — | WO | claimed |
| US-20090142279-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142279-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRNA3 | CHRM1 8/4885CHRM3 1/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.